成纤维细胞生长因子受体作为头颈部鳞癌放疗增敏靶点的研究
本研究评估泛FGFR抑制剂AZD4547在头颈部鳞癌细胞系和异种移植模型中增强放疗反应的能力,并分析FGFR1/2/3在患者样本中的表达。结果显示AZD4547在敏感细胞系中可显著增强放疗效果,机制涉及抑制MTOR通路、增强自噬和激活凋亡,在FGFR表达的异种移植模型中联合治疗显著延迟肿瘤生长。
要点
- AZD4547在敏感HNSCC细胞系中可显著增强放疗反应,机制涉及MTOR通路抑制和自噬增强。
- FGFR1/2/3 RNA原位杂交在口咽患者样本中表达率分别为41%、81%和89%。
- AZD4547联合放疗在FGFR表达的HNSCC异种移植和PDX模型中显著延迟肿瘤生长。
核心结论
- AZD4547可在FGFR表达的HNSCC体内模型中增强放疗反应,FGFR1和FGFR2可能是HNSCC放疗增敏的候选靶点。
研究设计与样本
- 在HNSCC患者样本、细胞系和患者来源异种移植(PDX)中评估FGFR1/2/3 RNA原位杂交表达。
- 体外评估AZD4547和放疗对细胞存活、FGFR信号、凋亡、自噬、细胞周期和DNA损伤修复的影响。
- 使用反相蛋白阵列鉴定AZD4547处理细胞中差异磷酸化蛋白。
- 在细胞系和PDX模型中评估体内肿瘤反应。
主要发现
- FGFR1、FGFR2和FGFR3 RNA原位杂交在107例口咽患者样本中的表达率分别为41%、81%和89%。
- 对AZD4547的敏感性与FGFR蛋白或RNA表达不直接相关。
- 在敏感细胞系中,AZD4547以时间依赖方式抑制p-MAPK。
- 在對AZD4547敏感的细胞系中观察到显著的放疗增敏效应。
- 在FGFR表达的HNSCC细胞系异种移植和PDX中,AZD4547联合放疗较单用放疗或单用药物显著延迟肿瘤生长。
关键数值与推荐
- FGFR1、FGFR2和FGFR3 RNA原位杂交在107例口咽患者样本中的表达率分别为41%、81%和89%。
临床怎么用
- FGFR1和FGFR2可能作为HNSCC临床研究中放疗增敏的候选靶点。
- AZD4547联合放疗在FGFR表达的HNSCC临床前模型中显示增强放疗反应的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We examined the capacity of the pan-fibroblast growth factor receptor (FGFR) inhibitor AZD4547 to augment radiation response across a panel of head and neck squamous cell carcinoma (HNSCC) cell lines and xenografts. METHODS AND MATERIALS: FGFR1, FGFR2, and FGFR3 RNA in situ hybridization expression was assessed in a cohort of HNSCC patient samples, cell lines, and patient-derived xenografts (PDXs). In vitro effects of AZD4547 and radiation on cell survival, FGFR signaling, apoptosis, autophagy, cell cycle, and DNA damage repair were evaluated. Reverse phase protein array was used to identify differentially phosphorylated proteins in cells treated with AZD4547. In vivo tumor responses were evaluated in cell lines and PDX models. RESULTS: FGFR1, FGFR2, and FGFR3 RNA in situ hybridization were expressed in 41%, 81%, and 89% of 107 oropharynx patient samples. Sensitivity to AZD4547 did not directly correlate with FGFR protein or RNA expression. In sensitive cell lines, AZD4547 inhibited p-MAPK in a time-dependent manner. Significant radiosensitization with AZD4547 was observed in cell lines that were sensitive to AZD4547. The mechanism underlying these effects appears to be multifactorial, involving inhibition of the MTOR pathway and subsequent enhancement of autophagy and activation of apoptotic pathways. Significant tumor growth delay was observed when AZD4547 was combined with radiation compared with radiation or drug alone in an FGFR-expressing HNSCC cell line xenograft and PDX. CONCLUSIONS: These findings suggest that AZD4547 can augment the response of radiation in FGFR-expressing HNSCC in vivo model systems. FGFR1 and FGFR2 may prove worthy targets for radiosensitization in HNSCC clinical investigations.
引用
- Fisher MM, SenthilKumar G, Hu R, et al. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys. 2020. PMID: 32298810. doi:10.1016/j.ijrobp.2020.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。